RxDoctor Payments Data

Maria Lozano, MD

Psychiatry · Winter Park, FLNPI 1891778809

Payments from drug & device makers

$994in general payments, 2019–2025

Across 54 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$188
  • Takeda Pharmaceuticals U.S.A., Inc.$186
  • Vanda Pharmaceuticals Inc.$153
  • Ironshore Pharmaceuticals Inc.$86
  • Otsuka America Pharmaceutical, Inc.$79
  • Shire North American Group Inc$70
  • plus $233 from 10 others

What the payments were for

  • Food & beverage$993100%
  • Gifts$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$994 in reported general payments places this provider in the 60th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$33,128
Medicare patients
90
Services billed
357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide15$10,124
FetzimaLevomilnacipran Hcl12$6,051
Quetiapine Fumarate177$3,276
Alprazolam353$2,551
Clonazepam239$2,173
Aripiprazole95$2,153
Bupropion XlBupropion Hcl120$1,851
Trazodone Hcl223$1,843
Duloxetine Hcl115$1,657
Buspirone Hcl136$1,585
Escitalopram Oxalate113$1,279
Mirtazapine73$1,221
Doxepin Hcl23$1,131
Hydroxyzine Hcl39$966
Fluoxetine Hcl107$955

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$186$10,12415 claims
AbbVieFetzima$70$6,05112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Winter Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →